Edap Tms (NASDAQ:EDAP) Share Price Crosses Above Two Hundred Day Moving Average – What’s Next?

Edap Tms S.A. (NASDAQ:EDAP) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.49 and traded as high as $4.50. Edap Tms shares last traded at $4.25, with a volume of 37,050 shares.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. HC Wainwright cut their target price on shares of Edap Tms from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Wall Street Zen lowered shares of Edap Tms from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $6.00.

Edap Tms Trading Down 0.7%

The firm has a market capitalization of $161.16 million, a P/E ratio of -5.31 and a beta of -0.10. The business’s 50-day moving average is $3.71 and its 200 day moving average is $3.51. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99.

Edap Tms (NASDAQ:EDAP) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). Edap Tms had a negative return on equity of 137.61% and a negative net margin of 41.47%.The business had revenue of $20.48 million for the quarter, compared to the consensus estimate of $19.46 million. As a group, analysts anticipate that Edap Tms S.A. will post -0.82 EPS for the current fiscal year.

Insider Buying and Selling

In other Edap Tms news, Director Joshua Levine purchased 10,000 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $4.22 per share, with a total value of $42,200.00. Following the completion of the transaction, the director owned 35,000 shares in the company, valued at $147,700. The trade was a 40.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.23% of the company’s stock.

Hedge Funds Weigh In On Edap Tms

Hedge funds have recently bought and sold shares of the company. Financial Planning Navigators CORP bought a new position in Edap Tms in the 4th quarter valued at about $33,000. SmartHarvest Portfolios LLC bought a new position in Edap Tms in the 1st quarter valued at about $38,000. Lido Advisors LLC bought a new position in Edap Tms in the 1st quarter valued at about $40,000. Kovack Advisors Inc. bought a new position in Edap Tms in the 4th quarter valued at about $53,000. Finally, Leonteq Securities AG bought a new position in Edap Tms in the 4th quarter valued at about $313,000. 62.74% of the stock is owned by institutional investors.

About Edap Tms

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.